Table 3.
Markers of inflammation, oxidative status, and cardiac fibrosis. All measures expressed relative to total serum protein content. TAC, Total antioxidant capacity; TNF-α, Tumor necrosis factor-α, IL-6, Interleukin-6; 4-HNE, Trans-4-Hydroxy-2-nonenal; PINP, Procollagen I N-terminal peptide; PIIINP, procollagen III N-terminal peptide.
| Variable | Group | Baseline | 4 Week | 8 Week | 16 Week | p Value |
|---|---|---|---|---|---|---|
| TAC | placebo | 6.06 ± 0.58 | 6.49 ± 0.78 | 6.30 ± 0.74 | 6.44 ± 0.91 | 0.583 |
| MSM | 6.37 ± 0.58 | 6.49 ± 0.61 | 6.75 ± 0.66 | 6.75 ± 0.60 | ||
| TNF-α | placebo | 6.46 ± 1.08 | 6.63 ± 1.07 | 6.72 ± 1.07 | 6.84 ± 1.08 | 0.498 |
| MSM | 7.84 ± 1.06 | 7.76 ± 1.00 | 7.63 ± 0.98 | 8.04 ± 1.13 | ||
| IL-6 | placebo | 1.75 ± 0.43 | 2.33 ± 0.59 | 2.17 ± 0.71 | 2.29 ± 0.66 | 0.319 |
| MSM | 1.79 ± 0.60 | 2.07 ± 0.67 | 1.76 ± 0.62 | 1.68 ± 0.57 | ||
| 4-HNE | placebo | 91.24 ± 20.91 | 96.63 ± 22.14 | 87.77 ± 21.5 | 85.75 ± 26.62 | 0.574 |
| MSM | 50.90 ± 6.58 | 55.01 ± 7.37 | 55.61 ± 8.51 | 49.88 ± 7.54 | ||
| PINP | placebo | 437.38 ± 98.32 | _ | _ | 363.27 ± 51.39 | 0.297 |
| MSM | 432.74 ± 77.78 | _ | _ | 460.38 ± 64.39 | ||
| PIIINP | placebo | 0.446 ± 0.130 | _ | _ | 0.680 ± 0.293 | 0.308 |
| MSM | 0.305 ± 0.077 | _ | _ | 0.533 ± 0.120 | ||
| PINP/PIIINP | placebo | 3691.512 ± 2714.35 | _ | _ | 2369.616 ± 945.108 | 0.311 |
| MSM | 1727.916 ± 601.482 | _ | _ | 899.000 ± 187.634 |